ACY-775

• Description :

  ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM[1][2]. ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) [3].

• UNSPSC :

  12352005

• Hazard Statement :

  H228, H315, H319

• Target :

  HDAC

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Neurological Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/ACY-775.html

• Purity :

  99.71

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(NO)C(C=N1)=CN=C1NC2(CCCCC2)C3=CC=CC(F)=C3

• Molecular Formula :

  C17H19FN4O2

• Molecular Weight :

  330.36

• Precautions :

  H228, H315, H319

• References & Citations :

  [1]Veronick Benoy, et al. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Neurotherapeutics. 2017 Apr; 14 (2) : 417-428.|[2]Jeanine Jochems et al. Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology. 2014 Jan; 39 (2) : 389-400.|[3]Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC3; HDAC6

• CAS Number :

  [1375466-18-4]